title: Partial adenosine A1 receptor agonists for cardiovascular therapies.
abstract: Adenosine, a purine nucleoside, is present in all cells in tightly regulated concentrations. It has many different physiological effects in the whole body and in the heart. Adenosine activates four G protein-coupled receptors A1, A2a, A2b, and A3. Activation of myocardial A1 receptors has been shown to inhibit a variety of myocardial pathologies associated with ischemia and reperfusion injury, including stunning, arrhythmogenesis, coronary and ventricular dysfunction, acute myocardial infarction, apoptosis, and chronic heart failure, implying several options for new cardiovascular therapies for diseases, like angina pectoris, control of cardiac rhythm, ischemic injury during an acute coronary syndrome, or heart failure. However, the main issue of using full A1 receptor agonists in such indications is the broad physiologic spectrum of cardiac and extracardiac effects. Desired A1 receptor-mediated protective and regenerative cardiovascular effects might be counter-regulated by unintended side effects when considering full A1 receptor agonists. These effects can be overcome by partial A1 agonists. Partial A1 agonists can be used to trigger only some of the physiological responses of receptor activation depending on endogenous adenosine levels and on receptor reserve in different tissues. CV-Therapeutics reported the identification of a partial A1 receptor agonist CVT-3619, and recently, another partial A1 receptor agonist VCP28 was published. Both compounds are adenosine derivatives. Adenosine-like A1 receptor agonists often have the drawback of a short half-life and low bioavailability, making them not suitable for chronic oral therapy. We identified the first non-adenosine-like partial A1 receptor agonist(s) with pharmacokinetics optimal for oral once daily treatment and characterized the qualities of the partial character of the A1 receptor agonist(s) in preclinical and clinical studies.
authors.affiliation: Research Center Wuppertal, Department of Heart Diseases, Institute of Cardiology, Bayer Pharma AG, Aprather Weg 18a, 42096, Wuppertal, Germany, barbara.albrecht@bayer.com.
authors.forename: Barbara E
authors.initials: BE
authors.lastname: Albrecht-Küpper
authors.forename: Kirsten
authors.initials: K
authors.lastname: Leineweber
authors.forename: Peter G
authors.initials: PG
authors.lastname: Nell
references.citation: Mol Pharmacol. 1996 May;49(5):915-26
references.pmid: 8622642
references.citation: Am J Physiol Heart Circ Physiol. 2003 Nov;285(5):H1797-818
references.pmid: 14561676
references.citation: Circ Res. 1990 Aug;67(2):406-14
references.pmid: 2376079
references.citation: Am J Physiol. 1993 Dec;265(6 Pt 2):H1916-27
references.pmid: 8285230
references.citation: Handb Exp Pharmacol. 2009;(193):161-88
references.pmid: 19639282
references.citation: Eur J Pharmacol. 1993 Jul 15;246(2):105-11
references.pmid: 8397091
references.citation: Nature. 1978 Dec 21-28;276(5690):839-41
references.pmid: 214714
references.citation: Cardiovasc Res. 2006 May 1;70(2):240-53
references.pmid: 16545352
references.citation: Am J Physiol Heart Circ Physiol. 2003 Jul;285(1):H81-9
references.pmid: 12637353
references.citation: Circ Res. 2005 Feb 18;96(3):363-7
references.pmid: 15653569
references.citation: Mol Pharmacol. 1997 Oct;52(4):683-91
references.pmid: 9380032
references.citation: J Am Coll Cardiol. 1998 Apr;31(5):1142-9
references.pmid: 9562020
references.citation: J Pharmacol Exp Ther. 2006 May;317(2):676-84
references.pmid: 16410404
references.citation: Br J Pharmacol. 1996 May;118(2):355-63
references.pmid: 8735638
references.citation: Pharmacol Rev. 2001 Dec;53(4):527-52
references.pmid: 11734617
references.citation: Pharmacol Rev. 1999 Dec;51(4):651-90
references.pmid: 10581327
references.citation: Mol Pharmacol. 1993 Jul;44(1):115-23
references.pmid: 8341267
references.citation: J Pharmacol Exp Ther. 2007 Apr;321(1):327-33
references.pmid: 17204748
references.citation: Brain Res. 2008 Jan 29;1191:69-74
references.pmid: 18163981
references.citation: Acta Anaesthesiol Scand. 2002 Feb;46(2):123-37
references.pmid: 11942859
references.citation: Handb Exp Pharmacol. 2009;(193):25-58
references.pmid: 19639278
references.citation: Antioxid Redox Signal. 2008 Feb;10(2):207-47
references.pmid: 17999631
references.citation: Circulation. 1992 Feb;85(2):659-65
references.pmid: 1735160
references.citation: Mol Pharmacol. 1989 Nov;36(5):681-8
references.pmid: 2511426
references.citation: Circ Res. 2003 Oct 17;93(8):759-66
references.pmid: 12970111
references.citation: Proc Natl Acad Sci U S A. 1980 May;77(5):2551-4
references.pmid: 6248853
references.citation: Am J Physiol Heart Circ Physiol. 2000 Nov;279(5):H2166-75
references.pmid: 11045950
references.citation: Cardiovasc Res. 2001 Oct;52(1):25-39
references.pmid: 11557231
references.citation: Handb Exp Pharmacol. 2009;(193):535-87
references.pmid: 19639293
references.citation: Prog Med Chem. 2009;47:163-201
references.pmid: 19328291
references.citation: Circ Res. 1995 Jul;77(1):194-8
references.pmid: 7788877
references.citation: Curr Top Med Chem. 2003;3(4):369-85
references.pmid: 12570756
references.citation: Mol Pharmacol. 2005 May;67(5):1385-7
references.pmid: 15703375
references.citation: Circulation. 1992 Mar;85(3):893-904
references.pmid: 1537125
references.citation: Cardiovasc Res. 2002 Aug 15;55(3):483-94
references.pmid: 12160945
references.citation: Curr Top Med Chem. 2004;4(8):839-54
references.pmid: 15078215
references.citation: Am J Physiol Heart Circ Physiol. 2001 Jan;280(1):H334-43
references.pmid: 11123249
references.citation: J Cardiovasc Pharmacol. 2010 Sep;56(3):282-92
references.pmid: 20571427
references.citation: Handb Exp Pharmacol. 2009;(193):189-214
references.pmid: 19639283
references.citation: J Biol Chem. 1987 Nov 15;262(32):15702-7
references.pmid: 3680221
references.citation: J Biol Chem. 1987 Jan 15;262(2):841-7
references.pmid: 3805010